Financials Scilex Holding Company

Equities

SCLX

US80880W1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
1.48 ^USD	-17.09%		-19.13%	-27.45%

06-14	Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa?) in Lumbosacral Radicular Pain	CI
06-12	Sector Update: Health Care Stocks Rise Premarket Wednesday	MT

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	564	199.6	179.3	-	-
Enterprise Value (EV) ¹	564	199.6	179.3	179.3	179.3
P/E ratio	-23.5 x	-1.59 x	-2.01 x	-3.04 x	-2.93 x
Yield	-	-	-	-	-
Capitalization / Revenue	-	4.27 x	2.98 x	2.01 x	2.02 x
EV / Revenue	-	4.27 x	2.98 x	2.01 x	2.02 x
EV / EBITDA	-	-	-	-	-
EV / FCF	-	-	-1.46 x	-1.62 x	-2.68 x
FCF Yield	-	-	-68.7%	-61.8%	-37.4%
Price to Book	-	-	-	-	-
Nbr of stocks (in thousands)	141,349	97,837	121,121	-	-
Reference price ²	3.990	2.040	1.480	1.480	1.480
Announcement Date	23-03-07	24-03-12	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	-	46.74	60.09	89.17	88.63
EBITDA	-	-	-	-	-
EBIT ¹	-	-105.4	-91.05	-88.8	-84.29
Operating Margin	-	-225.55%	-151.52%	-99.59%	-95.11%
Earnings before Tax (EBT) ¹	-	-114.3	-102.1	-95.77	-87.42
Net income ¹	-23.36	-114.3	-102.1	-95.77	-90.57
Net margin	-	-244.59%	-169.82%	-107.4%	-102.2%
EPS ²	-0.1700	-1.280	-0.7367	-0.4867	-0.5050
Free Cash Flow ¹	-	-	-123.2	-110.8	-67
FCF margin	-	-	-205.01%	-124.25%	-75.6%
FCF Conversion (EBITDA)	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	23-03-07	24-03-12	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2
Net sales ¹	-	10.12	13.46	10.88	13.17	16.03	20.01	20	21.7
EBITDA	-	-	-	-	-	-	-	-	-
EBIT ¹	-	-38.8	-18.34	-19.48	-26.42	-25.25	-25.78	-	-
Operating Margin	-	-383.56%	-136.23%	-178.96%	-200.58%	-157.53%	-128.8%	-	-
Earnings before Tax (EBT) ¹	-	-35.53	-21.39	-24.38	-30.08	-28.58	-29.04	-	-
Net income ¹	-26.65	-35.53	-21.39	-24.38	-30.08	-28.58	-29.04	-	-
Net margin	-	-351.18%	-158.87%	-223.97%	-228.39%	-178.29%	-145.1%	-	-
EPS ²	-0.1900	-0.6300	-0.2500	-0.2400	-0.1967	-0.1733	-0.1700	-0.1500	-0.1350
Dividend per Share	-	-	-	-	-	-	-	-	-
Announcement Date	23-08-11	23-11-14	24-03-12	24-05-13	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-
Net Cash position	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	-	-	-123	-111	-67
ROE (net income / shareholders' equity)	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-
Assets ¹	-	-	-	-	-
Book Value Per Share	-	-	-	-	-
Cash Flow per Share	-	-	-	-	-
Capex	-	-	-	-	-
Capex / Sales	-	-	-	-	-
Announcement Date	23-03-07	24-03-12	-	-	-

¹USD in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Scilex Holding Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.48 USD

Average target price

5.333 USD

Spread / Average Target

+260.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SCILEX HOLDING COMPANY	-27.45%	179M
KYOWA KIRIN CO. LTD.	+17.03%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-24.00%	4.44B
YUHAN CORPORATION	+13.37%	4.24B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.17%	4.03B
INDIVIOR PLC	+6.41%	2.14B
BETTA PHARMACEUTICALS CO., LTD.	-34.04%	1.9B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.56%	1.94B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-47.93%	1.63B

Specialty & Advanced Pharmaceuticals